{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:45:15Z","timestamp":1792507515947,"version":"4.5.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/md.0b013e31824125e4","type":"journal-article","created":{"date-parts":[[2011,12,24]],"date-time":"2011-12-24T05:19:23Z","timestamp":1324703963000},"page":"1-9","source":"Crossref","is-referenced-by-count":178,"title":["Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sj\u00f6gren Syndrome"],"prefix":"10.1097","volume":"91","author":[{"given":"Michael","family":"Voulgarelis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis D.","family":"Ziakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristea","family":"Papageorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Baimpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G.","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos M.","family":"Moutsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210309","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.2004.04993.x","article-title":"Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection.","volume":"126","author":"Ambrosetti","year":"2004","journal-title":"Br J Haematol"},{"key":"R2-1-20210309","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkins lymphoma. The International Non-Hodgkins Lymphoma Prognostic Factors Project.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"R3-1-20210309","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MD.0b013e3181b76ab5","article-title":"Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects.","volume":"88","author":"Baimpa","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"R4-1-20210309","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/rheumatology\/kem079","article-title":"Predicting adverse outcomes in primary Sjogrens syndrome: identification of prognostic factors.","volume":"46","author":"Brito-Zeron","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R5-1-20210309","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"R6-1-20210309","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"R7-1-20210309","first-page":"1674","article-title":"Local cytokine expression in the progression toward B cell malignancy in Sjogrens syndrome.","volume":"22","author":"De Vita","year":"1995","journal-title":"J Rheumatol"},{"key":"R8-1-20210309","first-page":"1361","article-title":"Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue.","volume":"151","author":"Dogan","year":"1997","journal-title":"Am J Pathol"},{"key":"R9-1-20210309","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.","volume":"111","author":"Ekstrom Smedby","year":"2008","journal-title":"Blood"},{"key":"R10-1-20210309","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1002\/art.11286","article-title":"Extrasalivary lymphoma development in Sjogrens syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering.","volume":"48","author":"Gasparotto","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R11-1-20210309","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy.","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"R12-1-20210309","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0961203308100481","article-title":"European consensus statement on the terminology used in the management of lupus glomerulonephritis.","volume":"18","author":"Gordon","year":"2009","journal-title":"Lupus"},{"key":"R13-1-20210309","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkins lymphoma.","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"R14-1-20210309","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogrens syndrome.","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R15-1-20210309","first-page":"531","article-title":"The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.","volume":"523-","author":"Jaffe","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R16-1-20210309","doi-asserted-by":"crossref","first-page":"888","DOI":"10.7326\/0003-4819-89-6-888","article-title":"Increased risk of lymphoma in sicca syndrome.","volume":"89","author":"Kassan","year":"1978","journal-title":"Ann Intern Med"},{"key":"R17-1-20210309","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/A:1018472213872","article-title":"Elevated incidence of hematologic malignancies in patients with Sjogrens syndrome compared with patients with rheumatoid arthritis (Finland).","volume":"8","author":"Kauppi","year":"1997","journal-title":"Cancer Causes Control"},{"key":"R18-1-20210309","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kei281","article-title":"Incidence of cancer in a cohort of patients with primary Sjogrens syndrome.","volume":"45","author":"Lazarus","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R19-1-20210309","first-page":"397","article-title":"Efficacy and safety profile of amifostine in the preoperative combined therapy of esophageal cancer patients.","volume":"7","author":"Orditura","year":"2000","journal-title":"Oncol Rep"},{"key":"R20-1-20210309","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/mpo.2950200403","article-title":"Lymphoma in Sjogrens syndrome.","volume":"20","author":"Pavlidis","year":"1992","journal-title":"Med Pediatr Oncol"},{"key":"R21-1-20210309","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogrens syndrome: an open-label phase II study.","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R22-1-20210309","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/ard.2004.030684","article-title":"Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogrens syndrome and associated MALT lymphoma.","volume":"64","author":"Pijpe","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R23-1-20210309","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1874312900802010038","article-title":"Resistance to rituximab therapy and local BAFF overexpression in Sjogrens syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma.","volume":"2","author":"Quartuccio","year":"2008","journal-title":"Open Rheumatol J"},{"key":"R24-1-20210309","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keh407","article-title":"Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogrens syndrome.","volume":"44","author":"Ramos-Casals","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R25-1-20210309","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.V90.2.766","article-title":"Lymphomas in patients with Sjogrens syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses.","volume":"90","author":"Royer","year":"1997","journal-title":"Blood"},{"key":"R26-1-20210309","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogrens syndrome.","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R27-1-20210309","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1440-1746.2008.05639.x","article-title":"Clinicopathological comparison of the World Health OrganizationWotherspoon score to the Groupe dEtude des Lymphomes de lAdult grade for the post-treatment evaluation of gastric mucosa-associated lymphoid tissue lymphoma.","volume":"24","author":"Shiozawa","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"R28-1-20210309","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","article-title":"Clinical evolution, and morbidity and mortality of primary Sjogrens syndrome.","volume":"29","author":"Skopouli","year":"2000","journal-title":"Semin Arthritis Rheum"},{"key":"R29-1-20210309","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jnci\/djj004","article-title":"Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype.","volume":"98","author":"Smedby","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"R30-1-20210309","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/art.11109","article-title":"Improvement in Sjogrens syndrome following therapy with rituximab for marginal zone lymphoma.","volume":"49","author":"Somer","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R31-1-20210309","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and other malignancies in primary Sjogrens syndrome: a cohort study on cancer incidence and lymphoma predictors.","volume":"65","author":"Theander","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R32-1-20210309","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/art.20176","article-title":"Mortality and causes of death in primary Sjogrens syndrome: a prospective cohort study.","volume":"50","author":"Theander","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R33-1-20210309","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","article-title":"Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed.","volume":"95","author":"Thieblemont","year":"2000","journal-title":"Blood"},{"key":"R34-1-20210309","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.1780390508","article-title":"Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogrens syndrome.","volume":"39","author":"Tzioufas","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R35-1-20210309","first-page":"2376","article-title":"Differential risk of non-Hodgkins lymphoma in Italian patients with primary Sjogrens syndrome.","volume":"24","author":"Valesini","year":"1997","journal-title":"J Rheumatol"},{"key":"R36-1-20210309","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogrens syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R37-1-20210309","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","article-title":"Malignant lymphoma in primary Sjogrens syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogrens Syndrome.","volume":"42","author":"Voulgarelis","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R38-1-20210309","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/ard.2005.046193","article-title":"Long term remission of Sjogrens syndrome associated aggressive B cell non-Hodgkins lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).","volume":"65","author":"Voulgarelis","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R39-1-20210309","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis.","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch Intern Med"},{"key":"R40-1-20210309","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.1999.17.4.1254","article-title":"Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients.","volume":"17","author":"Zinzani","year":"1999","journal-title":"J Clin Oncol"},{"key":"R41-1-20210309","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.","volume":"101","author":"Zucca","year":"2003","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0b013e31824125e4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:31:35Z","timestamp":1786048295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201201000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0b013e31824125e4","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}